Priority Research Papers:
PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2401 views | HTML 5736 views | ?
Abstract
Xiang Jiao1, Christos Aravidis1,2, Rajeshwari Marikkannu1, Johanna Rantala1, Simone Picelli1, Tatjana Adamovic1, Tao Liu1, Paula Maguire1, Barbara Kremeyer1, Liping Luo1, Susanna von Holst1, Vinaykumar Kontham1, Jessada Thutkawkorapin1, Sara Margolin3, Quan Du1, Johanna Lundin1, Kyriaki Michailidou4,5, Manjeet K. Bolla4, Qin Wang4, Joe Dennis4, Michael Lush4, Christine B. Ambrosone6, Irene L. Andrulis7,8, Hoda Anton-Culver9, Natalia N. Antonenkova10, Volker Arndt11, Matthias W. Beckmann12, Carl Blomqvist13, William Blot14,15, Bram Boeckx16,17, Stig E. Bojesen18,19,20, Bernardo Bonanni21, Judith S. Brand22, Hiltrud Brauch23,24,25, Hermann Brenner11,25,26, Annegien Broeks27, Thomas Brüning28, Barbara Burwinkel29,30, Qiuyin Cai14, Jenny Chang-Claude31,32, NBCS Collaborators33,34,35,36,37,38,39,40,41,42,43,44,45,46,47, Fergus J. Couch48, Angela Cox49, Simon S. Cross50, Sandra L. Deming-Halverson14, Peter Devilee51,52, Isabel dos-Santos-Silva53, Thilo Dörk54, Mikael Eriksson22, Peter A. Fasching12,55, Jonine Figueroa56,57, Dieter Flesch-Janys58,59, Henrik Flyger60, Marike Gabrielson22, Montserrat García-Closas57, Graham G. Giles61,62, Anna González-Neira63, Pascal Guénel64, Qi Guo65, Melanie Gündert29,30, Christopher A. Haiman66, Emily Hallberg67, Ute Hamann68, Patricia Harrington69, Maartje J. Hooning70, John L. Hopper62, Guanmengqian Huang68, Anna Jakubowska71, Michael E. Jones72, Michael J. Kerin73, Veli-Matti Kosma74,75,76, Vessela N. Kristensen37,41,42, Diether Lambrechts16,17, Loic Le Marchand77, Jan Lubinski71, Arto Mannermaa74,75,76, John W.M. Martens70, Alfons Meindl78, Roger L. Milne61,62, Anna Marie Mulligan79,80, Susan L. Neuhausen81, Heli Nevanlinna82, Julian Peto53, Katri Pylkäs83,84, Paolo Radice85, Valerie Rhenius69, Elinor J. Sawyer86, Marjanka K. Schmidt27,87, Rita K. Schmutzler88,89,90, Caroline Seynaeve70, Mitul Shah69, Jacques Simard91, Melissa C. Southey92, Anthony J. Swerdlow72,93, Thérèse Truong64, Camilla Wendt3, Robert Winqvist83,84, Wei Zheng14, kConFab/AOCS Investigators 94,95, Javier Benitez63,96, Alison M. Dunning69, Paul D.P. Pharoah4,69, Douglas F. Easton4,69, Kamila Czene22, Per Hall22 and Annika Lindblom1
1 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
2 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
3 Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden
4 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
5 Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
6 Roswell Park Cancer Institute, Buffalo, NY, USA
7 Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada
8 Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
9 Department of Epidemiology, University of California Irvine, Irvine, CA, USA
10 N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus
11 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
12 Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
13 Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
14 Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
15 International Epidemiology Institute, Rockville, MD, USA
16 VIB Center for Cancer Biology, VIB, Leuven, Belgium
17 Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium
18 Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
19 Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
20 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
21 Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy
22 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
23 Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
24 University of Tübingen, Tübingen, Germany
25 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
26 Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
27 Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
28 Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum, Bochum, Germany
29 Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
30 Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany
31 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
32 Research Group Genetic Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
33 Department of Oncology, Haukeland University Hospital, Bergen, Norway
34 Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
35 Department of Pathology, Akershus University Hospital, Lørenskog, Norway
36 Department of Breast-Endocrine Surgery, Akershus University Hospital, Lørenskog, Norway
37 Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
38 Department of Breast and Endocrine Surgery, Oslo University Hospital, Ullevål, Oslo, Norway
39 Department of Research, Vestre Viken Hospital, Drammen, Norway
40 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
41 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
42 Department of Clinical Molecular Biology, Oslo University Hospital, University of Oslo, Oslo, Norway
43 National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital Radiumhospitalet, Oslo, Norway
44 Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway
45 Department of Radiology and Nuclear Medicine, Oslo University Hospital Radiumhospitalet, Oslo, Norway
46 Oslo University Hospital, Oslo, Norway
47 Department of Oncology, Oslo University Hospital Ullevål, Oslo, Norway
48 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
49 Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
50 Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK
51 Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
52 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
53 Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
54 Gynaecology Research Unit, Hannover Medical School, Hannover, Germany
55 David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA
56 Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK
57 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
58 Institute for Medical Biometrics and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
59 Department of Cancer Epidemiology, Clinical Cancer Registry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
60 Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
61 Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia
62 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global health, The University of Melbourne, Melbourne, Victoria, Australia
63 Human Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain
64 Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif, France
65 Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
66 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
67 Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
68 Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
69 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
70 Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
71 Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
72 Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
73 School of Medicine, National University of Ireland, Galway, Ireland
74 Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland
75 Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland
76 Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
77 Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
78 Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany
79 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
80 Laboratory Medicine Program, University Health Network, Toronto, ON, Canada
81 Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA
82 Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
83 Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland
84 Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland
85 Department of Research, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy
86 Research Oncology, Guy’s Hospital, King’s College London, London, UK
87 Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands
88 Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, Cologne, Germany
89 Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany
90 Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
91 Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, QC, Canada
92 Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia
93 Division of Breast Cancer Research, The Institute of Cancer Research, London, UK
94 Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
95 The Sir Peter MacCallum Department of Oncology University of Melbourne, Parkville, Australia
96 Centro de Investigación en Red de Enfermedades Raras (CIBERER), Valencia, Spain
Correspondence to:
Annika Lindblom, email:
Keywords: familial breast cancer, linkage analysis, risk haplotype, sequencing
Received: July 06, 2017 Accepted: August 31, 2017 Published: October 12, 2017
Abstract
Most non-BRCA1/2 breast cancer families have no identified genetic cause. We used linkage and haplotype analyses in familial and sporadic breast cancer cases to identify a susceptibility locus on chromosome 6q. Two independent genome-wide linkage analysis studies suggested a 3 Mb locus on chromosome 6q and two unrelated Swedish families with a LOD >2 together seemed to share a haplotype in 6q14.1. We hypothesized that this region harbored a rare high-risk founder allele contributing to breast cancer in these two families. Sequencing of DNA and RNA from the two families did not detect any pathogenic mutations. Finally, 29 SNPs in the region were analyzed in 44,214 cases and 43,532 controls from BCAC, and the original haplotypes in the two families were suggested as low-risk alleles for European and Swedish women specifically. There was also some support for one additional independent moderate-risk allele in Swedish familial samples. The results were consistent with our previous findings in familial breast cancer and supported a breast cancer susceptibility locus at 6q14.1 around the PHIP gene.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21800